Acadian Asset Management
FATE icon

Acadian Asset Management’s Fate Therapeutics FATE Stock Holding History

Acadian Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
4,351,250
+231,050
+6% +$428K 0.01% 551
2026
Q1 		$4.94M Buy
4,120,200
+1,188,307
+41% +$1.45M 0.01% 719
2025
Q4 		$2.88M Buy
2,931,893
+221,659
+8% +$266K ﹤0.01% 818
2025
Q3 		$3.41M Buy
2,710,234
+250,280
+10% +$270K 0.01% 749
2025
Q2 		$2.75M Sell
2,459,954
-13,611
-0.6% -$15.8K 0.01% 743
2025
Q1 		$1.95M Buy
2,473,565
+999,773
+68% +$1.23M 0.01% 758
2024
Q4 		$2.43M Sell
1,473,792
-128,328
-8% -$323K 0.01% 719
2024
Q3 		$5.61M Sell
1,602,120
-406,742
-20% -$1.58M 0.02% 476
2024
Q2 		$6.59M Buy
2,008,862
+294,738
+17% +$1.29M 0.02% 435
2024
Q1 		$12.6M Sell
1,714,124
-567,047
-25% -$3.51M 0.04% 260
2023
Q4 		$8.53M Buy
2,281,171
+131,574
+6% +$311K 0.03% 328
2023
Q3 		$4.55M Buy
2,149,597
+1,236,680
+135% +$4.1M 0.02% 463
2023
Q2 		$4.34M Buy
+912,917
New +$5.04M 0.02% 493
2018
Q2 		– Sell
-10,347
Closed -$101K – 1748
2018
Q1 		$101K Buy
+10,347
New +$99.1K ﹤0.01% 1211
2016
Q1 		– Sell
-1,038
Closed -$3K – 1400
2015
Q4 		$3K Buy
+1,038
New +$4.36K ﹤0.01% 1335
2015
Q3 		– Sell
-306
Closed -$2K – 1336
2015
Q2 		$2K Buy
+306
New +$1.83K ﹤0.01% 1316

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management's FATE Position: Q2 2026 in Review

Acadian Asset Management increased its Fate Therapeutics (FATE) stake by 5.6% in Q2 2026, buying an estimated $428K and bringing the position to 4,351,250 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #551.

Acadian Asset Management first reported a position in FATE in Q2 2015 and has held it in 16 quarters since. The position peaked at $12.6M in Q1 2024. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Acadian Asset Management held 4,351,250 shares of Fate Therapeutics worth $11.7M as of Q2 2026.
  • Acadian Asset Management bought 231,050 Fate Therapeutics shares in Q2 2026, an estimated $428K.
  • Fate Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #551 holding.
  • Acadian Asset Management first reported a position in Fate Therapeutics in Q2 2015 and has held it in 16 quarters since.
  • Acadian Asset Management's Fate Therapeutics position peaked at $12.6M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.